Basal ¹⁸F-FDG PET/CT as a predictive biomarker of tumor response for neoadjuvant therapy in breast cancer

详细信息    查看全文

• 作者：A.M. Garcí ; a Vicente^a ; ^{angarvice@yahoo.es" class="auth_mail" title="E-mail the corresponding author} ; A. Soriano Castrejó ; n^a ; R.E. Pruneda-Gonzá ; lez^b ; G. Ferná ; ndez Calvo^b ; M.M. Muñ ; oz Sá ; nchez^c ; R. Á ; lvarez Cabellos^d ; R. Espinosa Aunió ; n^e ; F. Relea Calatayud^f
• 关键词：Locally advanced breast cancer ; 18F-FDG PET/CT ; Tumor kinetics ; Molecular phenotypes ; Neoadjuvant chemotherapy response
• 刊名：Revista Espa?ola de Medicina Nuclear e Imagen Molecular
• 出版年：2016
• 出版时间：March-April 2016
• 年：2016
• 卷：35
• 期：2
• 页码：81-87
• 全文大小：547 K

文摘

To explore the relation between tumor kinetic assessed by ¹⁸F-FDG PET and final neoadjuvant chemotherapy (NC) response within a molecular phenotype perspective.

Material and Methods

Prospective study included 144 women with breast cancer. All patients underwent a dual-time point ¹⁸F-FDG PET/CT previous to NC. The retention index (RI), between SUV-1 and SUV-2 was calculated.

Molecular subtypes were re-grouped in low, intermediate and high-risk biological phenotypes.

After NC, all residual primary tumor specimens were histopathologically classified in tumor regression grades (TRG) and response groups.

The relation between SUV-1, SUV-2 and RI with the TRG and response groups was evaluated in all molecular subtypes and in accordance with the risk categories.

Results

Responder's lesions showed significant greater SUVmax compared to non-responders. The RI value did not show any significant relation with response.

Attending to molecular phenotypes, statistical differences were observed with greater SUV for responders having high-risk molecular subtypes.

Conclusion

Glycolytic tumor characteristics showed a significant correlation with NC response and dependence of risk phenotype.